SAA1抗体;SAA1 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using SAA1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer tissues using SAA1 mouse mAb with DAB staining.    

  
  

The serum amyloid A1 (SAA1) protein is a major acute-phase reactant primarily synthesized in the liver and released into circulation during inflammatory responses. As a member of the SAA family, it plays a critical role in innate immunity, acting as a chemoattractant, modulating immune cell functions, and participating in lipid metabolism by associating with high-density lipoproteins (HDL). SAA1 levels rise dramatically (up to 1.000-fold) in response to infection, trauma, or chronic inflammation, making it a biomarker for conditions like rheumatoid arthritis, atherosclerosis, and cancer. However, persistent elevation of SAA1 is linked to pathological outcomes, notably amyloid A (AA) amyloidosis, where misfolded SAA1 aggregates deposit in tissues, causing organ dysfunction.

SAA1 antibodies are essential tools for detecting and quantifying SAA1 in research and diagnostics. These antibodies, often monoclonal or polyclonal, enable techniques like ELISA, Western blot, and immunohistochemistry to study SAA1 expression, localization, and its role in disease mechanisms. Recent studies also explore SAA1's potential as a therapeutic target, with antibodies being developed to neutralize its pro-inflammatory or amyloidogenic effects. Despite its well-characterized acute-phase role, ongoing research aims to unravel SAA1's dual functions in homeostasis and pathology, emphasizing its context-dependent roles in inflammation resolution versus chronic disease progression.